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Abstract 
Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lym-
phocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and 
subsequently inhibit further hair growth. Depending on the extent of involvement, alopecia 
areata can be associated with a dramatic reduction of quality of life. Currently, no targeted 
treatment option is available, and topical immune therapies or immunosuppressive drugs are 
typically used with mixed success. Recently, several cases of alopecia areata responding to 
Janus kinase inhibitors were published. Here, we report on a businessman with alopecia ar-
eata universalis who was treated with tofacitinib. We observed initial signs of hair regrowth in 
the same timeframe as previously reported, but efficacy quickly waned again, leading to re-
newed effluvium. Thus, even though tofacitinib and ruxolitinib are a promising new treat-
ment option, we have yet to learn more about their potential role in each particular patient’s 
individual treatment strategy. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Alopecia areata (AA), a nonscarring type of hair loss, is the most prevalent autoimmune 
disease, with a lifetime prevalence of 1.7% [1, 2]. Men and women are equally affected, and 
onset of the disease can occur at any age; however, most cases start before the age of 30 [3]. 
Fifty percent of children and adolescents with AA suffer from depression [4]. Autoimmune 
diseases such as vitiligo, thyroid disease and atopic diseases have been associated with AA 
[5]. The genetic architecture has also been described [6]. A high concordance rate among 
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monozygotic twins was reported [7, 8], and a positive family history is linked to AA [9–11]. 
Additionally, human leukocyte antigen (HLA)-DQB1, HLA-DRB1, HLA-A, HLA-B, HLA-C and 
also the genes NOTCH4, MICA, PTPN22 and AIRE were found to be associated with AA [2, 12]. 
The first genome-wide association study found 8 loci (table 1) with genome-wide signifi-
cance containing multiple genes involved in the adaptive T cell-driven immune response [2]. 
The current view is that both genetic and immune factors contribute to the development of 
AA (fig. 1). In addition, much less well-defined environmental and psychologic elements are 
sure to have some influence as well. 
A Cochrane review analyzing 17 randomized controlled trials concluded that there is 
currently no effective evidence-based treatment for AA. Even though topical minoxidil, cy-
closporine, corticosteroids (as well as systemic corticosteroids) and photodynamic therapy 
are used, there is no firm evidence of superiority compared to placebo [13]. However, in 
daily clinical use, all these drugs are used with apparent success. Recently, Suarez-Farinas et 
al. [14] performed microarray and RT-PCR of 27 lesional and 17 nonlesional samples of pa-
tients with AA. It was shown that TH1, TH2, and IL-23 cytokine were increased, while 
TH17/TH22 skewing was lacking [14]. Additionally, also ustekinumab, a monoclonal IL-
12/23 inhibitor, is of interest as a potential treatment of AA. There have been case reports 
that ustekinumab causes AA [15–17], but in contrast, successful treatments with significant 
increase of hair growth were reported [18, 19]. 
The possibility of reversal of AA by Janus kinase (JAK) inhibitors was successfully shown 
in the murine model [20]. Additionally, Craiglow and King [21] published a case of a 25-year-
old patient with psoriasis vulgaris and alopecia universalis, a type of AA in which complete 
loss of hair of the entire body is observed. After treatment with tofacitinib, a JAK1/3 inhibi-
tor approved for the treatment of rheumatoid arthritis, complete regrowth of hair was ob-
served [21]. Also, one case from Germany responded well to tofacitinib (U. Mrowietz, per-
sonal communication). In another case report, 3 patients suffering from AA were successful-
ly treated with ruxolitinib, a JAK1/2 inhibitor approved for myelofibrosis [20]. 
Case 
A 51-year-old businessman with alopecia universalis presented to our clinic. His past 
medical history revealed a bilateral chronic retinal vasculitis and uveitis, for which he had 
been treated in the past with various drugs such as methotrexate, azathioprine, oral predni-
solone and infliximab. Two years before, while receiving infliximab and azathioprine, sudden 
loss of hair had occurred on the temples, and drug-induced AA was suspected. Even though 
the drug treatment was stopped, the AA worsened. Four months later, the retinal vasculitis 
showed progression of disease as well, so infliximab and azathioprine were started again. A 
dermatologic consultation was sought. Subsequently, treatment with topical and oral ster-
oids, followed by topical diphenylcyclopropenone as well as oral methotrexate (up to 30 mg 
per week) was initiated. However, no regrowth of hair was observed after 6 months. 
Upon his first consultation in our clinic, a skin biopsy was performed on the scalp. A bi-
opsy confirmed sparse lymphocytic infiltrates along nonsclerotic fibrous tracts extending 
along the site of previous follicles. The diagnosis of a nonfibrosing AA was confirmed. Com-
passionate use of tofacitinib 5 mg twice daily was initiated. Methotrexate was continued at 
15 mg per week. The scalp remained unchanged for 2 months (fig. 2a), but after 3 months of 
treatment, growth of short terminal pigmented hair was detected (fig. 2b). These, however, 
disappeared again within a single month, resulting in renewed complete alopecia (fig. 2c). 
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Discussion 
The efficacy of tofacitinib has been suggested by murine experiments and by one case 
presentation [20, 21]. Tofacitinib citrate (Xeljanz®) abrogates IL-15 signaling [22] and thus 
mediates IL-15 activation of lymphocytes [14]. Even though the initial clinical results were 
promising, the efficacy of tofacitinib waned again in our patient. This was even more striking 
when considering that the patient had additional immunosuppression by methotrexate for 
his retinal vasculitis. Notably, methotrexate monotherapy has been shown to be a safe 
treatment option for AA as well [15]. Another potential reason for treatment failure could 
have been the presence of antibodies specific for hair follicles [23, 24]; however, we were 
unable to measure and rule them out. 
The clinical observation in this patient could be interpreted as follows: suppression of 
AA by tofacitinib is an active process that, if too weak, may not tip the balance towards stable 
hair regrowth but instead allow a reversion to a completely alopecic state. Although here we 
report only on a single case with all its limitations, it will be interesting to analyze the out-
come of randomized clinical trials, especially in patients not showing efficacy to tofacitinib. 
Also, our observation may prompt the question whether combinations of immunosuppres-
sive drugs potentiate or inhibit each other in AA. 
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Table 1. Loci with genome-wide association signals in AA 
  
  
Chromosome Immune genes associated with genome-wide signals 
  
  
2q33.2 CTLA4 gene encodes for CD152, an immune checkpoint that downregulates T cell re-
sponses 
    4q27 IL2/IL21 locus both promote CD8+ T cell function 
    6p21.32 HLA super locus which encodes for the histocompatibility leukocyte antigens. Especially, 
HLA class II loci have shown a strong association with AA 
    6q25.1 Cytomegalovirus UL16-binding protein gene cluster (ULBP3) encodes for NKG2D ligand 
3 and retinoic acid early transcript 1L protein, expressed especially on natural killer 
cells, but also on human CD8+ cytotoxic T cells and in some cases on CD4+ T cells 
    9q31.1 STX17 (Syntaxin-17) is a member of the soluble N-ethylmaleimide-sensitive factor-
attachment protein receptors (SNARE) superfamily, which is known for vesicular traf-
ficking and membrane fusion 
    10p15.1 IL2RA, also referred to as CD25, is associated with several autoimmune diseases and acts 
as a regulatory T cell marker 
    11q13 PRDX5 (Mitochondrial peroxiredoxin-5) is an oxidative stress-associated protein ex-
pressed in hair follicles and induces the elimination of DNA-damaging reactive oxygen 
species 
    12q13 Eos locus encodes for zinc finger proteins that can silence CD4+ regulatory T cells 
through mediation of the Foxp3-dependent gene [2, 20, 22] 
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Fig. 1. Genes and immunologic factors contributing to the pathogenesis of AA. 
 
 
 
Fig. 2. a Unchanged state of alopecia areata universalis even after 2 months of therapy. b shows the re-
growth of short terminal pigmented hair after 3 months, while c depicts the unfortunate relapse after 6 
months of tofacitinib therapy. 
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